ReviewInternational journal of ophthalmology2025
Retinoblastoma management in China: clinical challenges.
Review in International journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Post-translational modifications in retinoblastoma: mechanisms, immune regulation, and therapeutic opportunities.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinoblastoma (RB) is the most common intraocular malignancy in children. In recent years, advancements in chemotherapy-based comprehensive treatment approaches and diagnostic technologies have significantly improved long-term survival rates, shifting treatment goals from saving lives toward preserving vision and enhancing quality of life. In major RB treatment centers in China, survival rates have reached levels comparable to those in developed countries. However, in some underdeveloped regions, RB continues to pose a serious threat to affected children. To further improve survival rates and quality of life for RB patients and their families in China, a series of essential measures should be implemented. These include strengthening public education to raise awareness of RB, enhancing diagnostic efficiency, promoting standardized treatment protocols, providing genetic counseling and prenatal assessment for high-risk populations, and fostering the training of specialized healthcare professionals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.